Jcr Pharmaceuticals Co., Ltd. · TSE:4552

Jcr Pharmaceuticals — FY2014 Earnings Presentation

25 slides from Jcr Pharmaceuticals's earnings presentation, May 22, 2015

Slide 4: JR-041 JR-051 JR-032 pipeline
JR-041 / JR-051 α A JR-032 2 JR-131 JR-101 JR-141 NEW J-Brain Cargo -2- 2 CHO J MIG System J-MIG JR-142 NEW CHO J-MIG System JR-031 GVHD 2013 10 Copyright © 2015 JCR Pharmaceuticals Co., Ltd.
Slide 6: JR-141 and the blood-brain barrier
Hot Topics JR 141 : JR-141 Blood Brain Barrier : BBB) ¾ 95% BBB ¾ 100% BBB EMBO Molecular Medicine, 5, 655–657,2013 Aesthetic Medical Practitioner Copyright © 2015 JCR Pharmaceuticals Co., Ltd.
Slide 11: JR-142 growth hormone market
Hot Topics JR-142 : 2014 57% 16,855 18,000 15,075 EPO 16,000 , 14 387 14,457 14,387 14 457 14,099 14,000 12,845 11,871 12,082 12,000 2.5 % 10,000 8,000 6,000 4,000 2,000 0 2007 2008 2009 2010 2011 2012 2013 2014 4 1 3 31 Copyright © 2015 JCR Pharmaceuticals Co., Ltd.
Slide 12: Hot Topics: market shares and marketers
Hot Topics ¾ 2014 : 700 5% ¾ Merck Novo Serono Marketer Nordisk Pfizer Eli Lilly Fujifilm Sandoz** JCR Pharma 36% 30% 14% 1% 1% 18% ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ SGA ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ Copyright © 2015 JCR Pharmaceuticals Co., Ltd.
Slide 13: Hot Topics: competing development programs
Hot Topics ■ * Novo Nordisk A/S NNC0195-0092 Phase III in 2015 Teva Pharmaceutical Industries Ltd. TV-1106 Phase II in 2014 Pfizer, Inc. MOD-4023 Phase II in 2013 Versartis Inc. Versartis, Inc VRS 317 VRS-317 Phase II/III in 2015 * Copyright © 2015 JCR Pharmaceuticals Co., Ltd.
Slide 19: JR-031 (MSC) GVHD
R&D Pipeline JR 031 : JR-031 (MSC ) (MSCs) MSC 3,597 / 35 GVHD 0 GVHD 1,200 , / 35 MSC SC Copyright © JCR Pharmaceuticals Co., Ltd.
Slide 21: JR-051 (α-galactosidase A)
R&D Pipeline JR-051 : (α-galactosidase A) ■ α GL-3 GL 3 ■ X ■ * 300 ( ) 8 000 8,000 ( ) * ■ - : - : - : - : - : - : Copyright © JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals — FY2014 Earnings Presentation on 6ix

Jcr Pharmaceuticals — FY2014 Earnings Presentation

Slide 1: JCR Biotech for a New Tomorrow

Slide 2: Copyright © JCR Pharmaceuticals Co., Ltd.

Slide 3: Overview

Slide 4: JR-041 JR-051 JR-032 pipeline

Slide 5: Hot Topics / R&D Pipeline

Slide 6: JR-141 and the blood-brain barrier

Slide 7: J-Brain Cargo

Slide 8: JR-141 disease overview and market

Slide 9: JR-141 BBB development plan

Slide 10: J-Brain Cargo BBB

Slide 11: JR-142 growth hormone market

Slide 12: Hot Topics: market shares and marketers

Slide 13: Hot Topics: competing development programs

Slide 14: JR-142 (20K-GH HSA Fusion Protein)

Slide 15: Hot Topics / R&D Pipeline

Slide 16: JR-031 (MSCs)

Slide 17: JR-031 (MSCs)

Slide 18: JR-031 (MSCs) timeline

Slide 19: JR-031 (MSC) GVHD

Slide 20: JR-031 (MSC)

Slide 21: JR-051 (α-galactosidase A)

Slide 22: JR-051 collaboration

Slide 23: JR-131 (Darbepoetin alfa)

Slide 24: • JCR

Slide 25: Copyright © 2015 JCR Pharmaceuticals Co., Ltd.